This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Dates to which data relate
The effectiveness data were derived from sources published between 1984 and 2001. The price year was 2001.
Source of effectiveness data
The effectiveness data were derived from a review and synthesis of published sources.
Modelling
A decision analytic model was used to derive the cost-effectiveness of genotyping. In the model, one cohort of patients underwent CYP219 genotyping prior to the initiation of anti-H. pylori treatment, while the other did not undergo genotyping. Homozygous extensive metabolisers in the genotyped cohort received a non proton-pump inhibitor (PPI)-based regimen, which comprised bismuth, metronidazole, and tetracycline with ranitidine (BMTR). All other patients in both cohorts received a PPI-based regimen of omeprazole, amoxicillin and clarithromycin (OAC). All initial H. pylori eradication regimens were given for a week. DU recurrences associated with failure of the initial H. pylori treatment regimen in homozygous and heterozygous extensive metabolisers in the genotyped cohort were treated with high-dose lansoprazole plus amoxicillin for 2 weeks, whereas poor metabolisers in the genotyped cohort and nongenotyped patients received BMTR.
Outcomes assessed in the review
The outcomes assessed were: the H. pylori eradication rates according to the three treatment regimens for the three genotypes; the ethnic distribution of the CYP2C19 genotype; the regional US ethnic distribution; the DU recurrence rate when H. pylori was successfully eradicated and when eradication failed; and the DU complication rate requiring hospitalisation when H. pylori eradication failed.
Study designs and other criteria for inclusion in the review
The designs of the studies included in the review were not reported. However, the authors did report that the regional US ethnic distribution was derived from the 2000 Census.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 21 published studies were included in the review. Data from the 2000 US Census were also included.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The H. pylori eradication rate with OAC was 0.98 for a poor metaboliser of the CYP2C19 genotype, 0.92 for a heterozygous extensive metaboliser of the CYP2C19 genotype, and 0.73 for a homozygous extensive metaboliser of the CYP2C19 genotype.
The H. pylori eradication rate with BMTR was 0.86 for all three genotypes.
The H. pylori eradication rate with lansoprazole plus amoxicillin was 1.0 for those with heterozygous and homozygous extensive metaboliser genotypes.
The distribution of the CYP2C19 genotype in Asian or Pacific Islanders was 0.17 for poor metabolisers, 0.48 for heterozygous extensive metabolisers, and 0.35 for homozygous extensive metabolisers.
